Putrescine

Putrescine

SCHEMBL160836

NCCCCN.NCCCCN

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 1.00
DNM1 Q05193 9/20 0.88
CA12 O43570 3/20 0.88
CA1 P00915 3/20 0.88
CA2 P00918 3/20 0.88
CA3 P07451 3/20 0.88
CA4 P22748 3/20 0.88
CA6 P23280 3/20 0.88
CA5A P35218 3/20 0.88
CA7 P43166 3/20 0.88
CA9 Q16790 3/20 0.88
CA14 Q9ULX7 3/20 0.88
CA5B Q9Y2D0 3/20 0.88
TSHR P16473 3/20 0.88
LMNA P02545 1/20 0.88
BLM P54132 1/20 0.88
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
ALDH1A1 P00352 1/20 0.54
EPHX1 P07099 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Putrescine SCHEMBL21642 1.00
Putrescine SCHEMBL22227753 0.94
SCHEMBL7189680 0.94 DNM1 (1.00) NFKB1DNM1CA12CA1CA2
SCHEMBL887774 0.94 DNM1 (1.00) NFKB1DNM1CA12CA1CA2
Diaminooctane SCHEMBL8650707 0.94 DNM1 (1.00) NFKB1DNM1CA12CA1CA2
SCHEMBL25262966 0.94 DNM1 (1.00) NFKB1DNM1CA12CA1CA2
SCHEMBL22684930 0.94 DNM1 (1.00) NFKB1DNM1CA12CA1CA2
SCHEMBL22684932 0.94 DNM1 (1.00) NFKB1DNM1CA12CA1CA2
SCHEMBL22283336 0.94 DNM1 (1.00) NFKB1DNM1CA12CA1CA2
SCHEMBL16390420 0.94 DNM1 (1.00) NFKB1DNM1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113834927-A Salivary metabolism marker for predicting canceration of oral mucosa precancerous lesion patient and application thereof 南京市口腔医院 2021-12-24 CN claimed
CN-106635953-B Serum-free and protein-free cell culture medium 昆明润什生物科技有限公司 2021-02-19 CN claimed
CN-105969723-A Method for efficiently separating mouse spermatogonial stem cells 内蒙古大学 2016-09-28 CN claimed
US-5646236-A POLYAMINE REACTANT; METAL ELECTRODEPOSITION BATHS HOECHST AKTIENGESELLSCHAFT (DE) 1997-07-08 US claimed
US-12480131-B2 Tropane alkaloid (TA) producing non-plant host cells, and methods of making and using the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-11-25 US disclosed
EP-4591872-A1 COMPOSITION COMPRISING LACTOBACILLUS PLANTARUM STRAIN FOR IMPROVING INTESTINAL METABOLITE COMPOSITION Gi Biome Inc. (KR) 2025-07-30 EP disclosed
CN-120152723-A Composition for improving intestinal metabolite composition comprising lactobacillus plantarum strain GI生物群系公司 2025-06-13 CN disclosed
CN-113784758-B Non-plant host cells producing tropane alkaloids (TA) and methods of making and using the same 小利兰·斯坦福大学托管委员会 2025-03-07 CN disclosed
US-12215394-B2 Molecular marker nicotine associated SNP 1 for identifying high or low nicotine content of tobacco and its kit as well as use thereof YUNNAN ACADEMY OF TOBACCO AGRICULTURAL SCIENCES (CN) 2025-02-04 US disclosed
CN-118436656-A Application of evodiamine in regulating polyamine metabolism, YAP protein phosphorylation and nuclear translocation in colorectal cancer 重庆医科大学 2024-08-06 CN disclosed
US-20240191267-A1 Tropane Alkaloid Transporters and Methods of Making Tropane Alkaloids Using the Same HERCULES CAPITAL, INC., AS AGENT 2024-06-13 US disclosed
WO-2024058984-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2024-03-21 WO disclosed
US-20070259332-A1 Compositions and methods for simultaneous detection of volatile sulfur compounds and polyamines PDX BIOTECH LLC 2007-11-08 US disclosed
US-7196124-B2 Elastomeric material compositions obtained from castor oil and epoxidized soybean oil TEXAS TECH UNIVERSITY (US) 2007-03-27 US disclosed
US-20040235962-A1 Conformationally restricted polyamine analogs as disease therapies CELLGATE, INC. 2004-11-25 US disclosed
EP-1075254-A2 THE USE OF POLYAMINES IN THE TREATMENT OF DERMATOLOGICAL SYMPTOMS Ilenchuk, Theodore Toney (CA) 2001-02-14 EP disclosed
WO-1999051213-A2 THE USE OF POLYAMINES IN THE TREATMENT OF DERMATOLOGICAL SYMPTOMS ILENCHUK THEODORE TONEY (CA) 1999-10-14 WO disclosed
EP-0522758-B1 Surface-roughened film and method for fabricating thereof UNITIKA LTD (JP) 1998-05-27 EP disclosed
US-5354595-A Contains a thermoplastic resin, such as amorphous nylon, having glass transition temperature 10 degrees higher than that of polyester resin; critical surface tension; melt viscosity; shear rate UNITIKA, LTD. (JP) 1994-10-11 US disclosed
EP-0522758-A1 Surface-roughened film and method for fabricating thereof UNITIKA LTD. (JP) 1993-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235962-A1 Conformationally restricted polyamine analogs as disease therapies SRM, PYCR1, PAICS NFKB1 3815/4885DNM1 739/4885CA12 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.